What is P3 Health Partners's latest dividend and current dividend yield?

What were the key takeaways from P3 Health Partners's earnings call?

What is P3 Health Partners's gross profit margin?

What factors drove the changes in P3 Health Partners's revenue and profit?

What guidance did P3 Health Partners's management provide for the next earnings period?

What is the market's earnings forecast for P3 Health Partners next quarter?

Did P3 Health Partners beat or miss consensus estimates last quarter?

What does P3 Health Partners do and what are its main business segments?

- **Revenue & Margin Growth**: 6% capitated revenue growth, flat medical cost trend vs industry rise, and 5% premium rate increase for 2026. 
- **Profitability Roadmap**: $100M+ EBITDA improvement in 2025, targeting $120M-$170M expansion in 2026. 
- **Strategic Momentum**: 
  - 13,000 new ACO members added, 25,000+ MA pipeline, and 17.4% higher performance from Tier 1 providers. 
  - 500+ basis points gross margin expansion potential from stable medical trends and rate increases. 
- **Operational Strength**: 
  - $10.4M operating expense reduction, 33% YoY. 
  - 2026 EBITDA expansion 40% from risk alignment, 30% from clinical scale, 20% from contracts. 
- **Risk Management**: 
  - Q3 2025 $21M unfavorable settlement resolved with new controls. 
  - 2026 outlook: stable medical trends, 5% rate increase, and 500+ basis points margin expansion.

**【CEO Summary Section】**
- **Revenue Growth**: Capitated revenue increased 6% YoY, driven by improved burden of illness documentation and contract terms. Normalized medical cost trend remained flat YoY, outperforming industry averages.
- **EBITDA Improvement**: Achieved $100M+ EBITDA improvement YoY through operational restructuring and provider network optimization. 2026 EBITDA expansion opportunity of $120M-$170M, with 40% tied to population risk alignment and 30% to clinical program scale.
- **Strategic Initiatives**: 
  - 13,000 accretive ACO members added via joint venture, with 25,000+ Medicare Advantage pipeline for 2026.
  - Tier 1 provider alignment (17.4% higher closure rates vs non-Tier 1) and network rationalization (exit of non-aligned providers).

**【CFO Financial Commentary】**
- **Q3 2025 Results**: 
  - Adjusted EBITDA loss: $45.9M (Q3) / $85.2M (YTD). Normalized loss: $70.1M (YTD) after excluding prior period adjustments.
  - Operating expense reduction: $10.4M (33% YoY) through headcount alignment and reinvestment in clinical roles.
  - Medical margin: $4.4M (Q3) / $52.2M (YTD). Normalized medical cost trend stable YoY.
- **2026 Outlook**: 
  - $120M-$170M EBITDA expansion, with 20% from contractual improvements and 10% from product stabilization.
  - 5% premium rate increase (aggregate across markets) and 500+ basis points gross margin expansion potential.

**【Q&A Highlights】**
- **Payor Relationships**: 
  - 2026 benefit designs reflect more sustainable models, aligning with CMS rate environment. Payors recognize value of Care Enablement Model in managing high-risk patients.
  - 100% capitation model maintained, with bilateral accountability for outcomes.
- **Risk Management**: 
  - Midyear settlement adjustment of $21M in Q3 2025 (unfavorable). New controls implemented to improve visibility and predictability.
  - Single market headwinds (2025) expected to resolve in 2026 via contractual adjustments.
- **Performance Drivers**: 
  - 5% premium rate increase (aggregate) and 500+ basis points gross margin expansion potential.
  - 2026 medical cost trend expected to remain stable, with 40% of EBITDA opportunity tied to population risk alignment.


P3 Health Partners Inc. (PIII) Q3 2025 Earnings Call Transcript

- **Core Business Strength**: Medical cost trends remain flat YoY, outpacing industry with 3x improvement in care gap closures and 15% reduction in hospital admissions. 2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.
- **2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.
- **2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.


**【CEO Opening Remarks】**
- **EBITDA Improvement Plan Progress**: Near full execution of the $130 million EBITDA improvement plan. 3 out of 4 markets are breakeven or better through H1 2025.
- **Medical Cost Management**: Year-over-year medical cost trend is flat (excluding prior period adjustments), driven by effective cost management and clinical programs.
- **Contract Renegotiations**: Secured $20 million in contractual improvements, with 75% of priority payer contracts completed. $5 million EBITDA impact recognized in Q2.
- **Membership & EBITDA**: Q2 membership 115,000 (down 9% YoY). Adjusted EBITDA loss of $17 million, but normalized loss of $8 million (excluding $9 million prior period adjustments). Full year 2025 guidance revised to -$39M to -$69M.
- **2026 Outlook**: Targeting $120M-$170M EBITDA improvement, driven by CMS rate increases, benefit design rationalization, and operational efficiency gains.

**【CFO Financial Commentary】**
- **Revenue & Costs**: Capitated revenue $352M (down 6% YoY). Medical margin $39M ($114 PMPM), stable despite 6-7% industry medical cost inflation. Operating expenses down 13% YoY ($3M reduction) due to workforce optimization (25% reduction in non-core staff since Q1 2024).
- **Liquidity & Growth**: Ended Q2 with $39M liquidity. 2026 EBITDA improvement plan includes strategic joint venture adding 13,000-14,000 members with 15% surplus performance. 2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.
- **Financial Health**: 2025 normalized EBITDA loss improved to $22M H1 2025 (down 60% YoY). 2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.

**【CMO Clinical Update】
- **Care Enablement Model**: 65% of membership with Tier 1 providers. 2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.
- **Clinical Impact**: 3x improvement in care gap closures, 15% reduction in hospital admissions per 1,000 members, and 10% reduction in readmissions. 2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.
- **Clinical Programs**: 15% reduction in oncology costs, 43% increase in COPD enrollments. 2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.

**【Q&A Highlights】
- **Prior Period Adjustments**: $9M Q2 impact from delayed data from a national payer. 2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.
- **Contractual Improvements**: 2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.
- **2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.
- **2026 EBITDA improvement plan includes scaling clinical programs and optimizing provider networks.


P3 Health Partners Inc. (PIII) Q2 2025 Earnings Call Transcript

- **Strategic Momentum**: $130M EBITDA improvement plan 20% achieved in Q1, with 11% OpEx decline and 8% PMPM funding growth. 
- **Clinical Success**: ED visits down 21%, high-cost claims reduced 11%, and ACO REACH EBITDA up $5M sequentially. 
- **Risk Mitigation**: Single payer issue resolved with 2024 claims, 3/4 markets breakeven, and 2026 CMS rate +5% supporting long-term growth.

**【CEO Summary Section】**
- **2025 Guidance**: 3 of 4 markets achieved breakeven or better in Q1, with operational improvements expected to accelerate in Q2 and beyond. The company is on track to deliver $130M in EBITDA improvements through operating efficiency, contract renegotiations, and clinical execution.
- **Strategic Initiatives**: 
  - **Operating Efficiency**: $20M YoY improvement in OpEx, with 18% sequential decline in Q1. 
  - **Contracting**: $35M incremental EBITDA from payer renegotiations, including reduced Part D exposure and improved funding terms. 
  - **Clinical Execution**: Care enablement model adoption (Tier 1 providers) increased from 20% to 60% in Oregon, driving medical expense savings.
- **Q1 Results**: Total revenue of $373M (-4% YoY), membership down 8% YoY, but PMPM funding up 8% to $1,063. ACO REACH contributed $2M EBITDA, up $5M sequentially.

**【CFO Financial Details】**
- **Q1 Financials**: Adjusted EBITDA loss of $22M, driven by $23M claims from a single underperforming payer. Normalized MLR improved to 89% (vs. 96% FY24). 
- **Cost Control**: OpEx down 11% YoY, with reinvestment in frontline teams to support execution. 
- **Liquidity**: $40M cash on hand, with strong investor support for strategic initiatives.

**【Clinical Performance】**
- **Utilization Trends**: Admits per 1,000 down 3.2%, ED visits down 21%, SNF admissions down 22%. High-cost claims (>$20K) decreased 11%. 
- **Program Impact**: Complex care program on track for $30M savings in 2025, with 36% of target members enrolled. P3 Restore program reduced physician burnout, with 9 providers completing the 3-month program.

**【Q&A Highlights】**
- **EBITDA Improvements**: $130M plan back-end loaded, with Q1 achieving ~20% of OpEx savings and Q2+ seeing full impact of clinical initiatives. 
- **Payer Collaboration**: Outlier payer actively resolving 2024 claims, with 2026 benefit design improvements in pipeline. 
- **Market Performance**: 3/4 markets breakeven or better, with Oregon improving from 20% to 60% Tier 1 provider adoption.

P3 Health Partners Inc. (PIII) Q1 2025 Earnings Call Transcript

- **2025 Profitability Target**: Guided to achieve adjusted EBITDA of -$35M to +$5M, with $130M+ improvement from operational and contract initiatives.
- **Medical Margin Growth**: 2025 medical margin expected to rise to $174M-$210M, driven by reduced Part D risk (50% reduction in 2024) and benefit design changes.
- **Cash Position**: $54M starting cash in 2025, supported by $30M February inflow and Board-backed liquidity access.
- **Utilization Trends**: Early 2025 signs of improvement (25% high-cost case reduction in CA), offsetting Q4 2024 elevated costs.
- **Part D Exit**: Targeting full exit by 2027, with 50% reduction in 2024 and CMS 2026 bids signaling favorable trends.


**【CEO Opening Remarks】**
- **2025 Guidance**: Reaffirmed revenue of $1.35B-$1.5B and adjusted EBITDA of -$35M to +$5M, with a focus on profitable growth and achieving profitability this year.
- **EBITDA Improvement**: $130M+ opportunity through operational efficiencies ($20M), contract rationalization ($35M), and execution ($75M). Q1 2025 on track with $20M in cost savings and $35M in contract improvements.
- **Macro Environment**: Medicare sector improving due to CMS policy changes, with $30-$35 PMPM medical margin benefit from benefit design rationalization.
- **Leadership Expansion**: New hires include Shelly Martin (Regional Market President) and Todd Smith (Chief Legal & Compliance Officer), enhancing operational and compliance capabilities.

**【CFO Financial Review】**
- **Q4 2024 Results**: Revenue $371M (+7% YoY), adjusted EBITDA loss $68M (includes $17M one-time costs). Full-year 2024 revenue $1.5B (+18% YoY), adjusted EBITDA loss $167.2M.
- **2025 Outlook**: Medical margin $174M-$210M, driven by contract rationalization, affordability programs (hospice, palliative care), and reduced Part D risk (50% reduction in 2024, targeting full exit by 2026).
- **Liquidity**: $38.8M cash at year-end, with $15M received post-quarter, supporting $54M starting cash position for 2025.

**【CFO Q&A Highlights】**
- **Profitability Path**: 2025 EBITDA improvement of $153M (midpoint) includes $130M programmatic initiatives and $23M additional payer contract optimizations.
- **Seasonality**: Q1/Q4 typically lower due to utilization peaks, but 2025 Q1 showing early signs of improvement (e.g., 25% reduction in high-cost procedures in California).
- **Part D Risk**: 50% of membership no longer at Part D risk; 2026 CMS bids signal more favorable trends, with full exit targeted by 2027.

**【CMO Utilization Trends】**
- **Q4 2024 Challenges**: Elevated medical expenses (Part D, surgical utilization), but slight improvements in ER visits (-1%), observation rates (-3%), and SNP length of stay (17 to 19 days).
- **2025 Early Signs**: SNP length of stay improving to 14 days, hospice enrollment doubling (2.3% to 4%), and high-cost case reductions (25% in California, 12.5% in Nevada).
- **Care Enablement Model**: Field investments driving better documentation (20% YoY improvement in burden of illness assessments) and provider engagement (P3 Restore program reducing burnout).

**【Analyst Q&A Key Takeaways】**
- **Cash Management**: 2025 starting cash $54M, with $30M received in February to fund H1 operations; Board support for capital market access as needed.
- **Contract Negotiations**: 25% of payer contracts recontracted in 2025, targeting 50% by end of year; mutual alignment with payers on quality and cost control.
- **Specialty Expansion**: New oncology and musculoskeletal capitation contracts expected to reduce Part B drug spend and improve care coordination.


PIII

PIII fundamentals

Earnings Call

You can ask Aime